Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy
Authors:
- Maysa VilbertMVMaysa Vilbert
- Erica C. KochEKErica C. Koch
- April A.N. RoseARApril A.N. Rose
- Rob C. LaisterRLRob C. Laister
- Diana GrayDGDiana Gray
- Valentin SotovVSValentin Sotov
- Susanne PennySPSusanne Penny
- Anna SpreaficoASAnna Spreafico
- David HoggDHDavid Hogg
- Devanand M. PintoDPDevanand M. Pinto
- Marcus O. ButlerMBMarcus O. Butler
- Samuel D. SaibilSSSamuel D. Saibil
Preprint
- 31 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Cutaneous melanoma (CM) patients respond better to immune checkpoint inhibitors (ICI) than mucosal and uveal melanoma patients (MM/UM). Aiming to explore these differences and understand the distinct response to ICI, we evaluated the serum metabolome of advanced CM, MM, and UM patients. Levels of 115 metabolites were analyzed in samples collected before ICI, using a targeted metabolomics platform. In our analysis, molecules involved in the tryptophan-kynurenine axis distinguished UM/MM from CM. UM/MM patients had higher levels of 3-hydroxykynurenine (3-HKyn), whilst patients with CM were found to have higher levels of kynurenic acid (KA). The KA/3-HKyn ratio was significantly higher in CM versus the other subtypes. UM, the most ICI-resistant subtype, was also associated with higher levels of sphingomyelin-d18:1/22:1 and the polyamine spermine (SPM). Overall survival was prolonged in patients with lower SPM levels. Our study revealed distinct metabolomic profile between the most resistant melanoma subtypes, UM and MM, compared to CM. Alterations within the kynurenine pathway, polyamine metabolism and sphingolipid metabolic pathway may contribute to the poor response to ICI. Understanding the different metabolomic profiles introduces opportunities for novel therapies with potential synergic activity to ICI, to improve responses of UM/MM.Keywords
All Related Versions
- Version 1, 2023-05-31, Preprints
- Published version: Cancers, 15 (14), 3708.
This publication has 31 references indexed in Scilit:
- Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapyCancer Treatment Reviews, 2022
- Coenzyme A fuels T cell anti-tumor immunityCell Metabolism, 2021
- Role of ceramide/sphingomyelin (SM) balance regulated through “SM cycle” in cancerCellular Signalling, 2021
- Kynurenine emerges from the shadows – Current knowledge on its fate and functionPharmacology & Therapeutics, 2021
- Polyamines and Kynurenines at the Intersection of Immune ModulationTrends in Immunology, 2020
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyThe Lancet Oncology, 2019
- Sphingolipid metabolism in cancer signalling and therapyNature Reviews Cancer, 2017
- The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomicsMass Spectrometry Reviews, 2017
- The efficacy of anti‐PD‐1 agents in acral and mucosal melanomaCancer, 2016
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004